Globally, an estimated 40 million people live with HIV. Although 30·7 million of the people living with HIV have access to antiretroviral therapy, there were still 1·3 million new infections in 2022.1 ...
The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
The importance of developing a vaccine for herpes infections is highlighted by a new report showing one in five people live with most common form of genital infection .
The importance of developing a vaccine for herpes infections is highlighted by a new report showing one in five people live ...
Authorities say 70pc cases linked to unsafe sexual practices, reuse of syringes by unqualified practitioners, particularly in ...
Authorities say 70pc cases linked to unsafe sexual practices, reuse of syringes by unqualified practitioners, particularly in ...
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination, ...
A new study has revealed that daily oral antiretrovirals, like Truvada, are highly effective at preventing HIV when taken consistently alongside regular medical check-ups but their efficacy ...
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback